Stem-cell medicine sits at two extremes at once. At one end are established treatments such as blood stem-cell transplantation, used for decades with a large evidence base behind them. At the other is a fast-growing market of clinics offering unproven interventions directly to patients, often across borders, often at high prices, and often in jurisdictions where the rules have not caught up.
The Middle East and Africa (MEA) region could go either way. It has the patient demand, the medical-travel infrastructure and the capital to become a centre for advanced therapies. Without the right regulatory foundations, the same conditions attract the unproven end of the market, and the region's reputation pays for it.
What good regulation has to cover
International practice, including the guidelines of the International Society for Stem Cell Research, points to a handful of building blocks that every serious framework needs:
- Classification. A clear line between minimally manipulated cells used in established procedures and advanced therapy products that require full clinical evaluation.
- Manufacturing standards. Good Manufacturing Practice for cell processing, with licensed facilities and traceability from donor to patient.
- A clinical-trial pathway that is rigorous but fast enough to keep good science in the region rather than sending it elsewhere.
- Registries and outcome reporting, so that results, good and bad, are visible and comparable.
- Rules on advertising and patient consent, so that claims match the evidence.
Two ambitions
My first ambition is to help build an advisory team for governments in North Africa and across the MEA region: regulators, clinicians, scientists, health economists and legal specialists who can help ministries and health authorities design frameworks that protect patients and attract serious investment at the same time.
My second is to help build, with investor support, the largest hospital in the MEA region dedicated to advanced stem-cell treatment: a centre with its own cell-processing facility, a clinical-trials unit, a patient registry and a training programme, operating to international standards from the first day.
The order matters. Rules first, then trials, then scale. A hospital built ahead of its regulation is a liability; one built on it is a regional asset.
Why an energy strategist?
Because the problem has the same shape as a field development. A large, irreversible capital commitment, made on evidence that is still maturing, in a regulated environment where credibility is the scarcest resource. The discipline that works in energy works here: appraise before you develop, stage the capital, write down the kill criteria in advance, and benchmark every claim against what has actually been delivered elsewhere.
I intend to build this work with clinicians and scientists who lead the medicine. My role is the structure around it: the regulatory pathway, the investment case and the staged plan that makes it bankable.